p.87 抽出テキスト

395. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174–1183. https://doi.org/10.1016/S0140-6736(08)61242-8 396. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016;352:i438. https://doi.org/10.1136/bmj.i438 397. Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation 2020; 141:e779–e806. https://doi.org/10.1161/CIR.0000000000000766 398. Taggart DP, Audisio K, Gerry S, Robinson NB, Rahouma M, Soletti G Jr, et al. Single versus multiple arterial grafting in diabetic patients at 10 years: the Arterial Revascularization Trial. Eur Heart J 2022;43:4644–4652. https://doi.org/10.1093/ eurheartj/ehac199 399. Nyström T, Sartipy U, Franzén S, Eliasson B, Gudbjörnsdottir S, Miftaraj M, et al. PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll Cardiol 2017;70:1441–1451. 400. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, et al. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J 2021;42:4638–4651. https://doi.org/10.1093/eurheartj/ehab246 401. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364: 1607–1616. https://doi.org/10.1056/NEJMoa1100356 402. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012;5:476–490. https://doi.org/10.1161/CIRCINTERVENTIONS. 112.970954 402a. Newman JD, Anthopolos R, Mancini GJ, Bangalore S, Reynolds HR, Kunichoff DF, et al. Outcomes of participants with diabetes in the ISCHEMIA trials. Circulation 2021;144:1380–1395. https://doi.org/10.1161/CIRCULATIONAHA.121.054439 403. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am College Cardiol 2015;65:963–972. https://doi.org/10.1016/j. jacc.2014.12.038 404. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 386:665–671. https://doi.org/10.1016/S0140-6736(15)60648-1 405. Smits PC, Abdel-Wahab M, Neumann F-J, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017;376:1234–1244. https://doi.org/10.1056/NEJMoa1701067 406. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus culprit-only lesion intervention in patients with acute coronary syndromes. J Am College Cardiol 2018;72:1989–1999. https://doi.org/10.1016/j.jacc.2018.07.089 407. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J Am College Cardiol 2016;67:264–272. https://doi.org/10.1016/j.jacc.2015.10.082 408. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Eng J Med 2017; 377:2419–2432. https://doi.org/10.1056/NEJMoa1710261 409. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018;17:83. https://doi.org/10.1186/s12933-018- 0728-6 410. Aggarwal B, Shah GK, Randhawa M, Ellis SG, Lincoff AM, Menon V. Utility of glycated hemoglobin for assessment of glucose metabolism in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2016;117:749–753. https://doi.org/10.1016/j. amjcard.2015.11.060 411. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998;97: 2202–2212. https://doi.org/10.1161/01.cir.97.22.2202 412. Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol 2017;37:191–204. https://doi.org/10.1161/ ATVBAHA.116.306256 413. Henriksen EJ. A radical concept on caveolae and endothelial dysfunction in coronary microvascular disease in diabetes. Diabetes 2014;63:1200–1202. https://doi.org/10. 2337/db14-0057 414. Alabas O, Hall M, Dondo T, Rutherford MJ, Timmis A, Batin P, et al. Long-term excess mortality associated with diabetes following acute myocardial infarction: a populationbased cohort study. J Epidemiol Community Health 2017;71:25–32. https://doi.org/10. 1136/jech-2016-207402 415. Niedziela JT, Hiczkiewicz J, Kleinrok A, Pączek P, Leszek P, Lelonek M, et al. Prevalence, characteristics, and prognostic implications of type 2 diabetes in patients with myocardial infarction: the Polish Registry of Acute Coronary Syndromes (PL-ACS) annual 2018 report. Kardiol Pol 2020;78:243–246. https://doi.org/10.33963/KP.15189 416. Canto JG, Fincher C, Kiefe CI, Allison JJ, Li Q, Funkhouser E, et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol 2002; 90:248–253. https://doi.org/10.1016/S0002-9149(02)02463-3 417. O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am College Cardiol 2012;60:106–111. https://doi.org/10.1016/j. jacc.2012.02.059 418. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Pinto MD, Repaci S, et al. New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev 2010;6:102–110. https://doi.org/10.2174/1573399 10790909413 419. Goyal A, Mehta SR, Gerstein HC, Díaz R, Afzal R, Xavier D, et al. Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. Am Heart J 2009;157:763–770. https://doi.org/10.1016/j.ahj.2008.12.007 420. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117:1018–1027. https://doi.org/ 10.1161/CIRCULATIONAHA.107.740498 421. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am College Cardiol 1995;26:57–65. https://doi.org/10.1016/0735-1097(95) 00126-K 422. Zhao Y-T, Weng C-L, Chen M-L, Li K-B, Ge Y-G, Lin X-M, et al. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials. Heart 2010; 96:1622–1626. https://doi.org/10.1136/hrt.2010.194563 423. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am College Cardiol 2005;46:178–180. https://doi.org/10.1016/j.jacc.2005.03.052 424. Svensson A-M, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper-and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005;26:1255–1261. https://doi.org/10.1093/ eurheartj/ehi230 425. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–1297. https://doi.org/10.1056/ NEJMoa0810625 426. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2021;42:1289–1367. https://doi.org/10.1093/eurheartj/ehaa575 427. Malcolm J, Halperin I, Miller DB, Moore S, Nerenberg KA, Woo V, et al. In-hospital management of diabetes. Can J Diabetes 2018;42:S115–S123. https://doi.org/10. 1016/j.jcjd.2017.10.014 428. Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter randomized trial of intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes and recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes Care 2023;46:441–449. https://doi.org/10.2337/dc22-1219 429. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43: 4421–4432. https://doi.org/10.1093/eurheartj/ehac494 430. Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, et al. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes Vasc Dis Res 2015;12:23–32. https://doi. org/10.1177/1479164114551746 431. Timmer JR, Ottervanger JP, de Boer M-J, Boersma E, Grines CL, Westerhout CM, et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the primary coronary angioplasty vs thrombolysis–2 trial. Arch Intern Med 2007;167:1353–1359. https://doi.org/10.1001/ archinte.167.13.1353

ESC Guidelines                                                                                                                                                                                          4129

Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026